• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The story of multiple sclerosis: 1838-1993
3. The symptoms of multiple sclerosis
4. Pathogenesis of MS
5. Pathogenesis of MS: possible therapies
6. Pathological hetrogeneity in MS
7. Impairment of function and the MS clinical course
8. Reduced MS activity with interferon-beta-1b
9. Pivotal trials in relapsing-remitting MS (1)
10. Pivotal trials in relapsing-remitting MS (2)
11. Cochrane analysis of interferon efficacy
12. Monoclonal antibody trialed in MS
13. Pivotal trials of ZENAPAX (daclizumab): results
14. Nataluzimab\tysabru reduces relapse rate
15. Pivotal trials of tysabri - 2 year results
16. PML with tysbari
17. The story of Campath-1H treatment
18. Campath-1H causes prolonged T-cell depletion
19. Effects of the first dose of Campath-1H
20. Axonal damage is caused before conduction block
21. Campath-1H suppresses relapses in MS
22. Effect of Campath-1H on disability
23. Comparison of trials on Campath-1H and tysbari
24. Infections after Campath-1H
25. Graves' disease after Campath-1H treatment ( 1)
26. Graves' disease after Campath-1H treatment (2)
27. Immune trombocytopenia after Campath-1H
28. Autoimmune disease after Campath-1H
29. Other examples of reconstitution autoimmunity
30. Pathology and course of MS
31. Treatment of MS - 2006 and beyond

Topics Covered

• The story of multiple sclerosis
• Symptoms
• Pathogenesis
• Pathological heterogeneity
• Axonal degeneration
• Current treatments
• Interferons and glatiramer
• Monoclonal antibody treatment of multiple sclerosis
• Daclizumab
• Natalizumab
• The story of Campath-1H
• The effect of Campath-1H on disability depends upon the stage of the disease
• Graves' disease
• Immune thrombocytopenia
• Future treatment of multiple sclerosis

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Neurology

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Dr. Alasdair Coles has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
• Prof. Alastair Compston has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.